What is Longenesis?
Founded in 2017, Longenesis operates at the intersection of health-tech and data governance. The company provides an end-to-end environment designed to bridge the gap between biomedical institutions, patient advocacy groups, and research sponsors. Its platform specializes in safe data curation and consent-enabled utilization, ensuring that sensitive health information is managed with the highest regulatory rigor. By identifying metadata and onboarding population cohorts, Longenesis streamlines the complex process of clinical research, effectively reducing the friction typically associated with patient engagement and data acquisition in the biomedical sector.
How much funding has Longenesis raised?
Longenesis has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2021): $1.2M with participation from Rustam Gilfanov and Ilya Suharenko
Key Investors in Longenesis
Rustam Gilfanov
A prominent private investor and venture partner with a focus on high-growth technology startups and digital infrastructure.
Ilya Suharenko
An experienced investor specializing in early-stage capital allocation and strategic business development within the European technology landscape.
What's next for Longenesis?
With this major strategic investment, Longenesis is poised to accelerate its operational scaling and expand its footprint in key international markets. The company's roadmap likely involves enhancing its proprietary data curation algorithms and deepening its integration with global research partners. As the industry shifts toward more decentralized and patient-centric research models, Longenesis is well-positioned to capitalize on the increasing need for transparent, compliant, and efficient data utilization. Future growth will likely focus on strengthening its technological moat and expanding its network of biomedical institutions to support large-scale clinical trials and population health studies.
See full Longenesis company page
